Tan Wang, Liu Jiayu, Yu Renlin, Zhao Ping, Liu Yuhan, Lu Qian, Wang Ke, Ding Hao, Liu Yi, Lai Xiaofei, Cao Ju
Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Laboratory Medicine, The Seventh People's Hospital of Chongqing, Central Hospital Affiliated to Chongqing University of Technology, Chongqing, China.
PLoS Pathog. 2024 Nov 25;20(11):e1012747. doi: 10.1371/journal.ppat.1012747. eCollection 2024 Nov.
Candida albicans is the most common aetiologic pathogen of fungal infections associated with high mortality in immunocompromised patients. There is an urgent need to develop new antifungal therapies owing to the poor efficacy and resistance of current antifungals. Here, we report that Trim72 positively regulates antifungal immunity during lethal fungal infection. Trim72 levels are significantly increased after Candida albicans infection. In vivo, Trim72 knockout significantly increases mortality, organ fungal burden and kidney damage in mice after lethal Candida albicans infection. Whereas recombinant Trim72 protein treatment protects mice against invasive candidiasis. Mechanistically, Trim72 facilitates macrophage infiltration and CCL2 production, which mediates Trim72-elicited protection against lethal Candida albicans infection. Furthermore, Trim72 may enhance macrophage migration and CCL2 production via NF-κB and ERK1/2 signaling. Inhibition of NF-κB and ERK1/2 signaling abrogates Trim72-mediated protection against lethal Candida albicans infection. Therefore, these data imply that Trim72 may be developed as a host-directed therapy for treating severe systemic candidiasis.
白色念珠菌是免疫功能低下患者中与高死亡率相关的真菌感染最常见的病原体。由于目前抗真菌药物疗效不佳且存在耐药性,迫切需要开发新的抗真菌疗法。在此,我们报告Trim72在致死性真菌感染期间正向调节抗真菌免疫。白色念珠菌感染后,Trim72水平显著升高。在体内,Trim72基因敲除显著增加了致死性白色念珠菌感染后小鼠的死亡率、器官真菌负荷和肾脏损伤。而重组Trim72蛋白治疗可保护小鼠免受侵袭性念珠菌病的侵害。从机制上讲,Trim72促进巨噬细胞浸润和CCL2产生,这介导了Trim72对致死性白色念珠菌感染的保护作用。此外,Trim72可能通过NF-κB和ERK1/2信号增强巨噬细胞迁移和CCL2产生。抑制NF-κB和ERK1/2信号可消除Trim72介导的对致死性白色念珠菌感染的保护作用。因此,这些数据表明Trim72可能被开发为一种治疗严重全身性念珠菌病的宿主导向疗法。